Logo image of CRMD

CORMEDIX INC (CRMD) Stock Fundamental Analysis

NASDAQ:CRMD - Nasdaq - US21900C3088 - Common Stock - Currency: USD

10.13  -0.69 (-6.38%)

After market: 10.2 +0.07 (+0.69%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to CRMD. CRMD was compared to 194 industry peers in the Pharmaceuticals industry. CRMD has a great financial health rating, but its profitability evaluates not so good. CRMD is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CRMD had negative earnings in the past year.
CRMD had a negative operating cash flow in the past year.
CRMD had negative earnings in each of the past 5 years.
In the past 5 years CRMD always reported negative operating cash flow.
CRMD Yearly Net Income VS EBIT VS OCF VS FCFCRMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of CRMD (-59.48%) is worse than 67.03% of its industry peers.
CRMD has a Return On Equity (-78.60%) which is in line with its industry peers.
Industry RankSector Rank
ROA -59.48%
ROE -78.6%
ROIC N/A
ROA(3y)-48.42%
ROA(5y)-67.53%
ROE(3y)-54.98%
ROE(5y)-79.77%
ROIC(3y)N/A
ROIC(5y)N/A
CRMD Yearly ROA, ROE, ROICCRMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400 -500

1.3 Margins

The Gross Margin of CRMD (83.57%) is better than 90.27% of its industry peers.
The Profit Margin and Operating Margin are not available for CRMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRMD Yearly Profit, Operating, Gross MarginsCRMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K -40K

More info and screens

7

2. Health

2.1 Basic Checks

CRMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CRMD has more shares outstanding
The number of shares outstanding for CRMD has been increased compared to 5 years ago.
There is no outstanding debt for CRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRMD Yearly Shares OutstandingCRMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
CRMD Yearly Total Debt VS Total AssetsCRMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

An Altman-Z score of 13.34 indicates that CRMD is not in any danger for bankruptcy at the moment.
CRMD's Altman-Z score of 13.34 is amongst the best of the industry. CRMD outperforms 88.65% of its industry peers.
CRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 13.34
ROIC/WACCN/A
WACC9.77%
CRMD Yearly LT Debt VS Equity VS FCFCRMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 3.96 indicates that CRMD has no problem at all paying its short term obligations.
CRMD has a Current ratio (3.96) which is comparable to the rest of the industry.
CRMD has a Quick Ratio of 3.60. This indicates that CRMD is financially healthy and has no problem in meeting its short term obligations.
CRMD's Quick ratio of 3.60 is in line compared to the rest of the industry. CRMD outperforms 56.76% of its industry peers.
Industry RankSector Rank
Current Ratio 3.96
Quick Ratio 3.6
CRMD Yearly Current Assets VS Current LiabilitesCRMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

CRMD shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.81%.
CRMD shows a strong growth in Revenue. In the last year, the Revenue has grown by 40774.13%.
EPS 1Y (TTM)5.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.59%
Revenue 1Y (TTM)40774.13%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CRMD will show a very strong growth in Earnings Per Share. The EPS will grow by 39.20% on average per year.
CRMD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 321.29% yearly.
EPS Next Y55.41%
EPS Next 2Y62.39%
EPS Next 3Y46.57%
EPS Next 5Y39.2%
Revenue Next Year15623.5%
Revenue Next 2Y2184.56%
Revenue Next 3Y761.37%
Revenue Next 5Y321.29%

3.3 Evolution

CRMD Yearly Revenue VS EstimatesCRMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 200M 400M 600M
CRMD Yearly EPS VS EstimatesCRMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRMD. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 17.28, CRMD is valued on the expensive side.
81.62% of the companies in the same industry are more expensive than CRMD, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.68, CRMD is valued a bit cheaper.
Industry RankSector Rank
PE N/A
Fwd PE 17.28
CRMD Price Earnings VS Forward Price EarningsCRMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRMD Per share dataCRMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

CRMD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CRMD's earnings are expected to grow with 46.57% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y62.39%
EPS Next 3Y46.57%

More info and screens

0

5. Dividend

5.1 Amount

CRMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CORMEDIX INC

NASDAQ:CRMD (2/21/2025, 8:10:55 PM)

After market: 10.2 +0.07 (+0.69%)

10.13

-0.69 (-6.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-30 2024-10-30/bmo
Earnings (Next)03-10 2025-03-10/amc
Inst Owners29.9%
Inst Owner Change20.49%
Ins Owners1.02%
Ins Owner Change5.78%
Market Cap614.69M
Analysts81.82
Price Target16.52 (63.08%)
Short Float %12.05%
Short Ratio6.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.13%
Min EPS beat(2)1.96%
Max EPS beat(2)52.29%
EPS beat(4)3
Avg EPS beat(4)9.9%
Min EPS beat(4)-26.35%
Max EPS beat(4)52.29%
EPS beat(8)4
Avg EPS beat(8)4.41%
EPS beat(12)8
Avg EPS beat(12)8.99%
EPS beat(16)10
Avg EPS beat(16)7.9%
Revenue beat(2)1
Avg Revenue beat(2)-24.59%
Min Revenue beat(2)-52.8%
Max Revenue beat(2)3.62%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.82%
PT rev (3m)29.6%
EPS NQ rev (1m)165.96%
EPS NQ rev (3m)165.96%
EPS NY rev (1m)16.25%
EPS NY rev (3m)16.25%
Revenue NQ rev (1m)28.42%
Revenue NQ rev (3m)28.42%
Revenue NY rev (1m)20.34%
Revenue NY rev (3m)21.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 17.28
P/S 50.13
P/FCF N/A
P/OCF N/A
P/B 10.47
P/tB 10.82
EV/EBITDA N/A
EPS(TTM)-0.81
EYN/A
EPS(NY)0.59
Fwd EY5.79%
FCF(TTM)-0.93
FCFYN/A
OCF(TTM)-0.92
OCFYN/A
SpS0.2
BVpS0.97
TBVpS0.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -59.48%
ROE -78.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.57%
FCFM N/A
ROA(3y)-48.42%
ROA(5y)-67.53%
ROE(3y)-54.98%
ROE(5y)-79.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 204.79%
Cap/Sales 3.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.96
Quick Ratio 3.6
Altman-Z 13.34
F-Score2
WACC9.77%
ROIC/WACCN/A
Cap/Depr(3y)1040.29%
Cap/Depr(5y)652.53%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.59%
EPS Next Y55.41%
EPS Next 2Y62.39%
EPS Next 3Y46.57%
EPS Next 5Y39.2%
Revenue 1Y (TTM)40774.13%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year15623.5%
Revenue Next 2Y2184.56%
Revenue Next 3Y761.37%
Revenue Next 5Y321.29%
EBIT growth 1Y-22.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-126.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-131.61%
OCF growth 3YN/A
OCF growth 5YN/A